Home>Topics>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals VRTX

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. A Favorable Prognosis for This Pharma Stock

      Video Reports

      Thu, 18 Sep 2014

      Stefan Quenneville: We think [TICKER: VRTX ] Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant

      Vertex Pharmaceuticals VRTX found at 0:04

      Stefan Quenneville: We VRTX Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant player in this very
    2. Uncertainty Prevails For Vertex


      Thu, 11 Sep 2014

      By Balanced Investing : Following the successful approval and launch of Incivek, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) saw its revenue grow overnight in multiple folds in 2011. In no time, the drug crossed its

    3. Managing Expectations, Part II


      Tue, 19 Aug 2014

      which may face some tough competition if Albuferon receives Food and Drug Administration approval. We still think Vertex's VRTX Phase II telaprevir holds the most promise among hepatitis C drugs in development. Human Genome Sciences and partner Novartis

    4. Vertex to end sales of hepatitis C drug Incivek


      Wed, 13 Aug 2014

      Aug 13 (Reuters) - Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.

    5. PTC Therapeutics: A Speculative Buy On Rare Disease Portfolio And Potential Takeover Target


      Thu, 7 Aug 2014

      By Small Pharma Analyst : PTC Therapeutics (NASDAQ: PTCT ) has a mission to "leverage our knowledge of RNA biology to bring novel therapeutics to patients affected by rare and neglected disorders." The science at PTC is focused on discovering drugs that address so-called "nonsense" genetic ...

    6. Vertex's Price And Prospects Compared To Alexion


      Thu, 7 Aug 2014

      In the past, I have written fairly negative assessments on the value of Vertex (NASDAQ: VRTX ). See, for instance, " Vertex Pharmaceuticals , Dog Of The Nasdaq 100 Biotechs ". While listening to the Q2 2014 analyst conference, I started

    7. New Morningstar Analyst Report for Vertex Pharmaceuticals Inc

      Stock Reports

      Wed, 30 Jul 2014

      willing to sell material amounts of stock rather than maintain their shareholdings as long-term investors. Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. The firm's lead drug

    8. Reinvent Your Practice: Alternatives to Traditional Succession Planning


      Fri, 25 Apr 2014

      Worldwide UTIW Vertex Pharmaceuticals VRTX Walt Disney DIS ..... UTi Worldwide Vertex Pharmaceuticals Economic Moat ..... thinks Vertex's VRTX expertise in chronic ..... Analyst Report: Vertex Pharmaceuticals Walt Disney

    9. New Morningstar Analyst Report for BioMed Realty Trust Inc

      Stock Reports

      Fri, 20 Dec 2013

      including GlaxoSmithKline (9%; Morningstar Credit Rating A+), Regeneron Pharmaceuticals (8%, NR), Vertex Pharmaceuticals (7%; NR), and Beth Israel Deaconess Medical Center (5%; NR). BioMed recently derived 18% of its

    10. How Did Facebook End Up in the S&P 500?


      Tue, 17 Dec 2013

      Michael Kors Holdings KORS, Delta Air Lines DAL, News Corp NWSA, oil-services company Transocean RIG, and Vertex Pharmaceuticals VRTX . Meanwhile, those leaving the index included Dell, Sprint S, J.C. Penney JCP, Dean Foods DF, and

    « Prev12345Next »
    Content Partners